Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.85 USD
Change Today +0.10 / 1.29%
Volume 927.5K
SGMO On Other Exchanges
Symbol
Exchange
SGMO is not on other exchanges.
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Open
$7.65
Previous Close
$7.75
Day High
$7.89
Day Low
$7.65
52 Week High
03/20/15 - $19.25
52 Week Low
08/26/15 - $6.65
Market Cap
548.4M
Average Volume 10 Days
981.0K
EPS TTM
$-0.42
Shares Outstanding
69.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANGAMO BIOSCIENCES INC (SGMO)

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation. The company’s ZFPs can be linked to functional domains that regulate gene expression to create ZFP transcription factors (ZFP TFs) capable of activating or repressing a targeted gene. The ZFPs can also be linked to endonuclease domains to create zinc finger nucleases (ZFNs), which enable precise genome editing to facilitate the disruption of a specific gene or the targeted addition of a new gene or DNA sequence into the genome cells, without the detrimental consequences of off-target DNA binding activity. The Company’s lead ZFP Therapeutic candidate is SB-728-T, a ZFN-mediated autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). Sangamo BioSciences also has proprietary preclinical stage ZFP Therapeutic programs for lysosomal storage disorders such as Hunter and Hurler syndromes. In addition, the company has preclinical programs in hemophilia A and B, and Huntington’s disease in collaboration with Shire International GmbH; and hemoglobinopathies, such as beta-thalassemia and sickle cell disease in collaboration with Biogen Inc. Sangamo also has strategic partnerships with Sigma-Aldrich Corporation; Dow AgroSciences, LLC; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd; and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $650.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $405.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $440.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $460.0K
Compensation as of Fiscal Year 2014.

sangamo biosciences inc (SGMO) Key Developments

Sangamo Biosciences Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year 2015

Sangamo Biosciences Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s total revenues were $8.4 million compared with $10.4 million a year ago. The decrease in revenues compared to the year-ago quarter was primarily due to a decrease in revenue from the company's collaboration with Shire, partially offset by an increase in revenues from collaboration with Biogen. Loss from operations was $12.3 million compared with $7.0 million a year ago. Loss before taxes was $12.1 million compared with $6.98 million a year ago. Net loss was $12.1 million or $0.17 per basic and diluted share compared with $6.98 million or $0.10 per basic and diluted share a year ago. Net cash used in operating activities was $8 million. For the six months, the company’s total revenues were $21.8 million compared with $18.5 million a year ago. Loss from operations was $18.5 million compared with $14.7 million a year ago. Loss before taxes was $18.2 million compared with $14.6 million a year ago Net loss was $17.4 million or $0.25 per basic and diluted share compared with $14.6 million or $0.22 per basic and diluted share a year ago. Net cash used in operating activities was $10.4 million. For the year 2015, the company expects revenues will be in the range of $60 million to $70 million in 2015, inclusive of research funding from Biogen and research funding and certain milestone payments from Shire.

Sangamo Biosciences Inc. to Report Q2, 2015 Results on Aug 05, 2015

Sangamo Biosciences Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 05, 2015

Sangamo Biosciences Inc., Q2 2015 Earnings Call, Aug 05, 2015

Sangamo Biosciences Inc., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $7.85 USD +0.10

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $137.47 USD +4.11
Cellectis SA €29.46 EUR -0.03
Fibrocell Science Inc $5.74 USD +0.15
Spark Therapeutics Inc $45.62 USD +1.31
uniQure NV $25.77 USD +0.54
View Industry Companies
 

Industry Analysis

SGMO

Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.1x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit www.sangamo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.